The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
11 01 2021
11 01 2021
Historique:
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
24
6
2021
Statut:
ppublish
Résumé
The NCI-MATCH is a national master protocol trial, published in the Journal of Clinical Oncology, in which diverse tumors are sequenced and patients assigned to treatment. The trial demonstrates the feasibility of identifying rare and common actionable genetic alterations and underscores the strength of academic/community partnerships for improving trial access.
Identifiants
pubmed: 33434511
pii: S1535-6108(20)30669-3
doi: 10.1016/j.ccell.2020.12.021
pmc: PMC10640715
mid: NIHMS1734089
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-24Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of Interest A.D. acknowledges receipt of honoraria and/or has served on advisory boards for the following companies: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis,Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, and Melendi. He further discloses associated research paid to the institution from: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, and PharmaMar. He has received research support from Foundation Medicine and royalties from Wolters Kluwer. Z.K.S. acknowledges that an immediate family member in ophthalmology receives consulting and/or advisory role fees from Genentech/Roche, Neurogene, Novartis, Adverum, Allergan, Gyroscope Tx, Regeneron, RegenexBio, and Optos Plc.
Références
J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029
pubmed: 31922567
Lancet Oncol. 2020 Dec;21(12):1589-1601
pubmed: 33125909
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074
pubmed: 29506128
J Clin Oncol. 2020 Nov 20;38(33):3883-3894
pubmed: 33048619
Nat Med. 2020 Dec;26(12):1852-1858
pubmed: 33106665
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):143-145
pubmed: 29254888
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
J Clin Oncol. 2020 Nov 20;38(33):3895-3904
pubmed: 32758030
JCO Precis Oncol. 2022 Jul;6:e2200165
pubmed: 35939768